Cardiovascular disease (CVD) is one of the leading causes of morbidity and mortality worldwide, particularly in older people. 1 The combination of the ageing process, altered metabolic and hemodynamic function, and reduced physical activity in patients with CVDs can lead to muscular loss and sarcopenia. 2 Sarcopenia is described as an age-related decline in skeletal muscle mass and muscle function. 3 Sarcopenia may result in adverse outcomes such as reduced physical capability, poorer quality of life, increased risk of falls, disability, mortality and high health care expenditure. 3 In 2016, sarcopenia received its own International Classification of Diseases 10th Revision (ICD-10) code, which highlights the need for the recognition of sarcopenia by practising clinicians. 4 Studies in Western countries showed that the prevalence of sarcopenia was around 20% among people aged ≥65 years and up to 50%-60% in people aged ≥80. 5 In Asia, studies from Japan, Korea, China, Taiwan and Thailand have shown that the prevalence of sarcopenia in older people ranged from around 10% to 30%. 3 Vietnam is a country in SouthEast Asia experiencing rapid urbanisation and an ageing population. Due to the population ageing and the population size, the impact of sarcopenia in Vietnam may be high, especially in older people with CVD. However, there has been no study of sarcopenia